Abstract
Epigenetic targets are exciting new avenues for cancer drug discovery. Zhang and colleagues have designed the open-source EZH2 inhibitor JQEZ5 and shown antitumor efficacy in vitro and in vivo in preclinical studies in murine and human lung adenocarcinoma models expressing high levels of EZH2.
Original language | English (US) |
---|---|
Pages (from-to) | 949-952 |
Number of pages | 4 |
Journal | Cancer discovery |
Volume | 6 |
Issue number | 9 |
DOIs | |
State | Published - Sep 2016 |
ASJC Scopus subject areas
- Oncology